3344-18-1O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2]PLSARIKBYIPYPF-UHFFFAOYSA-H3344-18-1DTXSID601015151CHEMBL3989480This chemical does not meet GHS hazard criteria for 98.7% (74 of 75) of all reports.
Not Classified;Reported as not meeting GHS hazard criteria by 74 of 75 companies (only 1.3% companies provided GHS information). For more detailed information, please visit ECHA C&L website.
Aggregated GHS information provided per 75 reports by companies from 2 notifications to the ECHA C&L Inventory.;Reported as not meeting GHS hazard criteria per 74 of 75 reports by companies.;There is 1 notification provided by 1 of 75 reports by companies with hazard statement code(s).;Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Chemical: 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, magnesium salt(2:3)
Regulation (EC) No 1331/2008
Status: Active Update: 28-09-2021 https://echa.europa.eu/registration-dossier/-/registered-dossier/10972
Magnesium Citrate: Does not have an individual approval but may be used under an appropriate group standard
B - Blood and blood forming organs;B05 - Blood substitutes and perfusion solutions;B05C - Irrigating solutions;B05CB - Salt solutions;B05CB03 - Magnesium citrate
A - Alimentary tract and metabolism;A06 - Drugs for constipation;A06A - Drugs for constipation;A06AD - Osmotically acting laxatives;A06AD19 - Magnesium citrate
A - Alimentary tract and metabolism;A12 - Mineral supplements;A12C - Other mineral supplements;A12CC - Magnesium;A12CC04 - Magnesium citrate
QA - Alimentary tract and metabolism;QA06 - Drugs for constipation;QA06A - Drugs for constipation;QA06AD - Osmotically acting laxatives;QA06AD19 - Magnesium citrate
QB - Blood and blood forming organs;QB05 - Blood substitutes and perfusion solutions;QB05C - Irrigating solutions;QB05CB - Salt solutions;QB05CB03 - Magnesium citrate
QA - Alimentary tract and metabolism;QA12 - Mineral supplements;QA12C - Other mineral supplements;QA12CC - Magnesium;QA12CC04 - Magnesium citrate
The onset of action can be as early as 30 minutes after administration with a mean onset time of approximately 2 hours and a maximum action of 4 hours. The effect of magnesium citrate is highly dependent on the individual's hydration status.
MAGESIUM CITRATE
Osmotic Activity [MoA]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]; Calculi Dissolution Agent [EPC]; Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]; Increased Large Intestinal Motility [PE]; Osmotic Laxative [EPC]; Magnesium Ion Exchange Activity [MoA]; Inhibition Small Intestine Fluid/Electrolyte Absorption [PE]
Wird geladen…
CHEBI:131391◉ Summary of Use during Lactation;No information is available on the clinical use of magnesium citrate during breastfeeding. However, other magnesium salts have been studied. Intravenous magnesium sulfate increases milk magnesium concentrations only slightly. Oral absorption of magnesium by the infant is poor, so maternal magnesium citrate is not expected to affect the breastfed infant's serum magnesium. Magnesium citrate supplementation during pregnancy might delay the onset of lactation, but it can be taken during breastfeeding and no special precautions are required.;◉ Effects in Breastfed Infants;Fifty mothers who were in the first day postpartum received 15 mL of either mineral oil or an emulsion of mineral oil and another magnesium salt, magnesium hydroxide equivalent to 900 mg of magnesium hydroxide, although the exact number who received each product was not stated. Additional doses were given on subsequent days if needed. None of the breastfed infants were noted to have any markedly abnormal stools, but all of the infants also received supplemental feedings.;◉ Effects on Lactation and Breastmilk;One mother who received intravenous magnesium sulfate for 3 days for pregnancy-induced hypertension had lactogenesis II delayed until day 10 postpartum. No other specific cause was found for the delay, although a complete work-up was not done. A subsequent controlled clinical trial found no evidence of delayed lactation in mothers who received intravenous magnesium sulfate therapy. Some, but not all, studies have found a trend toward increased time to the first feeding or decreased sucking in infants of mothers treated with intravenous magnesium sulfate during labor because of placental transfer of magnesium to the fetus.;A study in 40 pairs of matched healthy women with vaginally delivered singleton pregnancies, outcome endpoints were compared in those receiving continuous oral magnesium aspartate HCl supplementation mean dose of 459 mg daily (range 365 to 729 mg of magnesium daily) for at least 4 weeks before delivery versus non-supplemented controls. In the magnesium group, significantly fewer women could breastfeed their infants exclusively at discharge (63% vs 80%).
Chemical: 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, magnesium salt(2:3)
Regulation (EC) No 1331/2008
Status: Active Update: 28-09-2021 https://echa.europa.eu/registration-dossier/-/registered-dossier/10972
Magnesium Citrate: Does not have an individual approval but may be used under an appropriate group standard
MAGNESIUM CITRATE
Inhibition Small Intestine Fluid/Electrolyte Absorption [PE]; Magnesium Ion Exchange Activity [MoA]; Osmotic Laxative [EPC]; Increased Large Intestinal Motility [PE]; Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]; Calculi Dissolution Agent [EPC]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]; Osmotic Activity [MoA]
Mean plasma concentration of magnesium after administration of oral doses of magnesium citrate are reported to be of around 0.7 mmol/L and the concentration in saliva rested in 0.28 mmol/L. In reports, it has also been proven that the absorption and bioavailability of magnesium are greater when administered in the form of magnesium citrate when compared with other forms such as magnesium ocude.
After oral administration of magnesium citrate, there is a 40% increase in urine excretion of magnesium. Magnesium citrate is also widely eliminated via the feces because, when present in the bowel, it relaxes the bowel and pulls water into the intestine which increases bowel movement and a significant portion of this agent gets excreted by this via.
BeschreibungTrimagnesium dicitrate is a high-purity magnesium salt, it is primarily utilized as a Magnesium source in food products, dietary supplements, and pharmaceuticals.
VerwendenTrimagnesium Dicitrate is used in the preparation of Cyclopentadiene Magnesium Ferrite nanomaterial. As a versatile compound, it is primarily utilized as a magnesium source in food products, dietary supplements, and pharmaceuticals. Its anhydrous form offers distinct advantages, such as low moisture content, making it especially stable and suitable for sensitive formulations.
DefinitionChEBI: Trimagnesium dicitrate is a magnesium salt composed of magnesium and citrate ions in a 3:2 ratio. It has a role as a laxative. It contains a citrate(3-).